Accellacare not only exceeds enrollment goals on our #obesity studies, we retain 92% of those patients. By offering patient centric services, like in-home visits and concierge services, we can reduce the patient and caregiver burden. Learn more: https://ow.ly/HLkr50SJ03L #patientretention #patient #accellacare
Info
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.
- Website
-
http://www.iconplc.com
Externer Link zu ICON plc
- Branche
- Biotechnologieforschung
- Größe
- 10.001+ Beschäftigte
- Hauptsitz
- Dublin
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Spezialgebiete
- Medical Device, Therapeutics, Government and Public Health Solutions, Clinical Research Services, Commercialisation and Outcomes, Oncology, Value Based Healthcare, Clinical Trials, Patient Recruitment, Innovation, Regulatory Affairs, Strategic Consulting, Medical Affairs und Global Patient Insights & Engagement
Orte
Beschäftigte von ICON plc
Updates
-
Bioanalysis of immunogenicity is critical for the development of therapeutic proteins, as immunogenicity can affect both the safety and efficacy of biologic drugs. High-quality approaches for tiered detection, characterization, or quasi-quantification of anti-drug antibodies (ADAs) require up-to-date knowledge of analytical methodologies, regulatory guidelines and industry best practices. To ensure high-quality approaches for immunogenicity testing, it is necessary to grasp a wide understanding of the needs and expectations of companies that are developing drugs that may initiate immunogenicity. Flexibility in approaches is needed to serve the different needs of each program. In this Spotlight hosted by Bioanalysis Zone we explore the elements involved in the different approaches for immunogenicity assessment, including preclinical ADA assessments, singlicate ADA analysis, or complex assay strategies to determine ADAs for different compounds/antibody modalities. https://ow.ly/7tMR50SCg05
-
-
Symphony Health, an ICON plc company, is pleased to announce the publication of a significant study leveraging our real-world data to explore the prevalence of tendon rupture and tendinopathies among patients with atherosclerotic cardiovascular disease (ASCVD). This retrospective, observational study provides critical insights that can help healthcare providers assess the underlying risk factors and guide more effective treatment plans for this vulnerable patient population. Click here to explore the findings and their implications for clinical practice: https://ow.ly/PyyZ50SJOZx. #HealthcareResearch #ASCVD #RealWorldData #SymphonyHealth
-
-
Accellacare offers experience in phase II-IV obesity studies involving most major drug classes including: GLP-1 receptor agonist, SGLT-2 inhibitors, DP-4 Inhibitors, Insulin and Insulin Analogs, and Alpha Glucosidase Inhibitors just to name a few. Learn more about our experience: https://ow.ly/BXOO50SIZS1
-
-
We are pleased to highlight our DAWN community group at ICON! DAWN is dedicated to disability advocacy,creating connections, and driving initiatives that enhance accessibility. It’s a supportive platform where we grow in understanding workplace well-being and create positive change. DAWN empowers us to bring our commitment to disability advocacy back to our teams for a tangible impact. To understand more about our community groups at ICON please follow the below link: https://ow.ly/zZxE50SKjbM
-
-
The benefits of new combination vaccines, from simplifying vaccination schedules to reducing pressure on health care systems, are numerous. Read the latest blog from ICON infectious disease experts. https://ow.ly/QJtq50SCXXn
-
-
Accellacare consistently exceeds enrollment goals for obesity studies - on average, we enroll 129% of our #obesity study targets in under 4 months. Learn more: https://ow.ly/vPGs50SIZJl
-
-
The convergence of big data and artificial intelligence has opened new avenues for enhancing clinical research. In this article in The Clinical Trial Vanguard, Travis Caudill, Vice President, Feasibility, Site Identification & Clinical Informatics at ICON, explores how human-enabled AI is improving site selection. Read the article here: https://ow.ly/RAcR50SHTM5 #AI #siteselection #clinical research
-
-
As technology has advanced, the classifications of medicinal products and medical devices have become ever more complicated, as have their regulatory requirements. In this blog we focus extensively on the EU regulatory regime, and contrast with that in the US. https://ow.ly/PuuZ50SJWJi
-
-
Will you be at ADLM 2024 in Chicago? What are most looking forward to? Our Medical Devices and Diagnostics Research team can’t wait to meet with you in booth #5237. Stop by to learn how we can support the development of your in vitro diagnostic products. https://ow.ly/x48o50SwJ7a
-
Verbundene Seiten
Ähnliche Seiten
Finanzierung
ICON plc
Insgesamt 1 Finanzierungsrunde
Weitere Informationen auf Crunchbase
Letzte Runde
Fremdkapital nach Börsengang
Externer Crunchbase-Link für die letzte Finanzierungsrunde
2.000.000.000,00 $